Biocon Biologics completes acquisition of Viatris biosimilars biz for $3.3 bn
Biocon Biologics, Viatris get all key approvals from global regulators, including US FTC, CCI, RBI, and investors. Biocon Ltd’s stake in Biocon Biologics to rise to 68%.
viatris
November 2022
February 2022
Bold bet! Biocon Biologics buys Viatris biosimilars assets for $3.33 billion
Viatris will receive $2 billion in cash and up to $335 million as additional payments expected to be paid in 2024.
